IRhythm Technologies : 2025 Proxy Season Shareholder Engagement

Published: 2025-05-11 23:58:04 ET IRTC

Published on 05/11/2025 at 23:58

iRhythm Technologies 2025 Proxy Season Shareholder Outreach

May 2025

$158.7 million

First quarter 2025 revenue, a 20.3% increase compared to first quarter 2024

2+ million

Patient reports posted annually

27+ million

Potential patients in the United States who could benefit from ambulatory cardiac monitoring*

5+ million tests

Target market opportunity across prioritized EU and APAC countries*

Over 30%

penetration in core

U.S. ambulatory cardiac monitoring market as of

December 31, 2024

10+ million

Patient reports posted since company inception through March 31, 2025

125+

Original scientific research manuscripts

2.5+ billion

Hours of curated ECG data since company

inception thru 2024

Data on file. iRhythm Technologies, May 2025. *See sources in appendix for 'Multiple levers for long-term growth and sustainable value creation' and 'International opportunity represents $1+ billion TAM with 5+ million tests in prioritized countries across EMEA and Asia Pacific'

Compelling investment thesis for long-term shareholder value creation

MARKET EXPANSION

OPPORTUNITIES INNOVATION

OPERATIONAL

EFFICIENCY FOCUS

IMPROVING

FINANCIAL PROFILE

Core US market penetration Greenfield specialist growth Primary care physician growth Channel expansion International expansion Adjacent market development

Relentless patient focus Clinical insight generation

AI and prediction capabilities Connected care

Commitment to quality, safety

and regulatory compliance Supply chain resilience Unit cost economics Digital transformation

Continuous process

improvement

Focus on generating leverage

Disciplined opportunity prioritization

Balanced reinvestments

Strategic portfolio management

Investments for opening

adjacent markets

Long-term strategy to deliver enhanced value to all stakeholders

iRhythm on a journey to evolve and mature our corporate profile

Leadership

Team

Board

Evolution

Operational

Transformation

Fiscal Discipline & Responsibility

Best-in-class Quality Management System

Reimbursement pathway settled

Transition to profitability

Expanding global reach

Multi-sensing capabilities

PROGRESS TO DATE

Board evolution

Enhanced corporate governance measures, including multiple material weaknesses eliminated

Elevated corporate sustainability focus

New leadership team

Maturing compensation programs aligned with investor interests

UNANTICIPATED HEADWINDS

FDA Warning Letter

Quality systems remediation

DOJ investigation

Disclaimer

IRhythm Technologies Inc. published this content on May 12, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 12, 2025 at 03:57 UTC.